Overview

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
Evaluation of the Efficacy and Safety of Romiplostim N01 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (CTIT) in Patients with Leukemia
Phase:
PHASE2
Details
Lead Sponsor:
Anhui Provincial Hospital